251 related articles for article (PubMed ID: 11736938)
1. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases.
García-Sanz R; Montoto S; Torrequebrada A; de Coca AG; Petit J; Sureda A; Rodríguez-García JA; Massó P; Pérez-Aliaga A; Monteagudo MD; Navarro I; Moreno G; Toledo C; Alonso A; Besses C; Besalduch J; Jarque I; Salama P; Rivas JA; Navarro B; Bladé J; Miguel JF;
Br J Haematol; 2001 Dec; 115(3):575-82. PubMed ID: 11736938
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of Waldenström macroglobulinaemia--the experience of one centre].
Adam Z; Pour L; Krejcí M; Korístek Z; Navrátil M; Krivanová A; Zahradová L; Hájek R
Vnitr Lek; 2009 Jan; 55(1):9-17. PubMed ID: 19227950
[TBL] [Abstract][Full Text] [Related]
3. Waldenström macroglobulinemia.
Gertz MA
Hematology; 2012 Apr; 17 Suppl 1():S112-6. PubMed ID: 22507796
[TBL] [Abstract][Full Text] [Related]
4. Circulating low CD4
Cao X; Kong YL; Wang L; Liang JH; Xia Y; Zhu HY; Fan L; Jiang SH; Liu H; Li JY; Xu W
Ann Hematol; 2021 Apr; 100(4):995-1002. PubMed ID: 33651193
[TBL] [Abstract][Full Text] [Related]
5. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
Leblond V; Johnson S; Chevret S; Copplestone A; Rule S; Tournilhac O; Seymour JF; Patmore RD; Wright D; Morel P; Dilhuydy MS; Willoughby S; Dartigeas C; Malphettes M; Royer B; Ewings M; Pratt G; Lejeune J; Nguyen-Khac F; Choquet S; Owen RG
J Clin Oncol; 2013 Jan; 31(3):301-7. PubMed ID: 23233721
[TBL] [Abstract][Full Text] [Related]
6. Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil.
Kyle RA; Greipp PR; Gertz MA; Witzig TE; Lust JA; Lacy MQ; Therneau TM
Br J Haematol; 2000 Mar; 108(4):737-42. PubMed ID: 10792277
[TBL] [Abstract][Full Text] [Related]
7. Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia.
Abeykoon JP; Zanwar S; Ansell SM; Winters J; Gertz MA; King RL; Murray D; Habermann T; Dingli D; Muchtar E; Go RS; Leung N; Inwards DJ; Buadi FK; Dispenzieri A; Lacy MQ; Lin Y; Gonsalves WI; Kourelis T; Witzig TE; Thompson C; Vincent Rajkumar S; Kyle RA; Kumar S; Kapoor P
Am J Hematol; 2018 Nov; 93(11):1384-1393. PubMed ID: 30121949
[TBL] [Abstract][Full Text] [Related]
8. [Waldenstrom macroglobulinemia].
Kolyvanos Naumann U; Käser L; Vetter W
Praxis (Bern 1994); 2004 Mar; 93(14):547-52, 577. PubMed ID: 15125068
[No Abstract] [Full Text] [Related]
9. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia.
Gustine JN; Meid K; Dubeau T; Hunter ZR; Xu L; Yang G; Ghobrial IM; Treon SP; Castillo JJ
Br J Haematol; 2017 Jun; 177(5):717-725. PubMed ID: 28485115
[TBL] [Abstract][Full Text] [Related]
10. Clinical features of Waldenstrom macroglobulinemia in Korea.
Bang SM; Park SR; Park SH; Cho EK; Yoon SS; Shin DB; Lee JH; Park S; Kim BK; Kim NK
Korean J Intern Med; 2004 Sep; 19(3):137-40. PubMed ID: 15481603
[TBL] [Abstract][Full Text] [Related]
11. Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit.
Kyrtsonis MC; Vassilakopoulos TP; Angelopoulou MK; Siakantaris P; Kontopidou FN; Dimopoulou MN; Boussiotis V; Gribabis A; Konstantopoulos K; Vaiopoulos GA; Fessas P; Kittas C; Pangalis GA
Ann Hematol; 2001 Dec; 80(12):722-7. PubMed ID: 11797112
[TBL] [Abstract][Full Text] [Related]
12. Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2015 Apr; 90(4):346-54. PubMed ID: 25808108
[TBL] [Abstract][Full Text] [Related]
13. A review of Waldenstrom's macroglobulinemia.
McDermott MK; Bell EM
Clin J Oncol Nurs; 1999 Jul; 3(3):107-11. PubMed ID: 10690041
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).
Dhodapkar MV; Jacobson JL; Gertz MA; Rivkin SE; Roodman GD; Tuscano JM; Shurafa M; Kyle RA; Crowley JJ; Barlogie B
Blood; 2001 Jul; 98(1):41-8. PubMed ID: 11418461
[TBL] [Abstract][Full Text] [Related]
15. Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Buske C; Leblond V; Dimopoulos M; Kimby E; Jäger U; Dreyling M;
Ann Oncol; 2013 Oct; 24 Suppl 6():vi155-9. PubMed ID: 24078658
[No Abstract] [Full Text] [Related]
16. Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis.
Annibali O; Petrucci MT; Martini V; Tirindelli MC; Levi A; Fossati C; Del Bianco P; Mandelli F; Foa R; Avvisati G
Cancer; 2005 Feb; 103(3):582-7. PubMed ID: 15611977
[TBL] [Abstract][Full Text] [Related]
17. Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2013 Aug; 88(8):703-11. PubMed ID: 23784973
[TBL] [Abstract][Full Text] [Related]
18. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival.
García-Sanz R; Dogliotti I; Zaccaria GM; Ocio EM; Rubio A; Murillo I; Escalante F; Aguilera C; García-Mateo A; García de Coca A; Hernández R; Dávila J; Puig N; García-Álvarez M; Chillón MDC; Alcoceba M; Medina A; González de la Calle V; Sarasquete ME; González M; Gutiérrez NC; Jiménez C
Br J Haematol; 2021 Mar; 192(5):843-852. PubMed ID: 32780894
[TBL] [Abstract][Full Text] [Related]
19. Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2012 May; 87(5):503-10. PubMed ID: 22508368
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases.
Facon T; Brouillard M; Duhamel A; Morel P; Simon M; Jouet JP; Bauters F; Fenaux P
J Clin Oncol; 1993 Aug; 11(8):1553-8. PubMed ID: 8336194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
